Risk of stroke, TIA, MACE and major bleeding events during vitamin K-antagonist treatment stratified by renal function within the entire population.

Definitions: no-CKD = estimated glomerular filtration rate (eGFR) >60 ml/min, moderate CKD = eGFR 30–60 ml/min, severe CKD = eGFR Abbreviations: CKD = chronic kidney disease, PY = patient years, CI = confidence interval, HR = hazard ratio, MACE = major adverse cardiovascular event, TIA = transient ischemic attack.‡Reported incidences for patients with an eGFR 30–60 or eGFR >60 ml/min are influenced by sampling of patients matched for age and gender to those with an eGFR * HR adjusted for age, gender, hypertension, the use of platelet-inhibitors, diabetes mellitus and congestive heart failure.†HR adjusted for age and gender. Further correcting resulted in non-converging coefficients.